Barthalomew Jung-Sillah

Barthalomew (B.A.) Jung-Sillah is an accomplished professional in the healthcare and pharmaceutical industries, currently serving as Vice President of Business Development and Consultant at Thetis Pharmaceuticals since October 2024. Jung-Sillah holds multiple advisory and leadership roles, including Investment Committee Member at Penn Medicine – Wharton Fund for Health, Managing Partner at Kola Global, and Investment Advisor for Health and Digital Health at Ben Franklin Technology Partners. Previously, Jung-Sillah has held significant positions such as Chief Business Officer and Chief Operating Officer at Avesta76 Therapeutics, Executive-In-Residence at Drexel University's School of Biomedical Engineering, Strategy Consultant at the African Union, and various roles at Militia Hill Ventures and Talee Bio. Academic credentials include a Doctor of Medicine from the University of Pennsylvania School of Medicine, an M.B.A. in Healthcare Management from The Wharton School, and a Bachelor of Arts in Human Developmental and Regenerative Biology from Harvard University.